

(19) World Intellectual Property
Organization
International Bureau



Rec'd PCT/PTO 21 JAN 2005



10/521927

(43) International Publication Date
29 January 2004 (29.01.2004)

PCT

(10) International Publication Number
WO 2004/009087 A1

(51) International Patent Classification⁷: A61K 31/506,
A61P 35/00 Avenue, Wherry Hall G7, Cincinnati, OH 45267-0829
(US).

(21) International Application Number:
PCT/IB2003/001984

(74) Agents: HOXIE, Thomas et al.; c/o Novartis AG, Corporate
Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date: 23 May 2003 (23.05.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR,
TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(26) Publication Language: English

Published:


— with international search report

(71) Applicant (*for all designated States except US*): UNIVERSITY OF CINCINNATI [US/US]; Mail Location 627, Cincinnati, OH 45221-0627 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): FAGIN, James,
Alexander [US/US]; University of Cincinnati, 3223 Eden



A1

(54) Title: 4-(METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE FOR TREATING MUTATED-RET KINASE ASSOCIATED DISEASES

(57) Abstract: The invention relates to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof for the treatment of mutated-RET kinase associated disease, especially mutated-RET kinase associated thyroid cancer.